The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous
Names

None

Entity Type

0001512762 BioGenerics, Inc. X Corporation

Name of Issuer Limited Partnership

Coherus BioSciences, Inc.

Limited Liability Company

Jurisdiction of General Partnership
Incorporation/Organization

Business Trust

DELAWARE Business Trust
Other (Specify)

Year of Incorporation/Organization

Over Five Years Ago

X Within Last Five Years (Specify Year) 2010 Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Coherus BioSciences, Inc.

Street Address 1 Street Address 2

C/O DENNIS M. LANFEAR 201 REDWOOD SHORES PARKWAY, SUITE 200

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

REDWOOD CITY CALIFORNIA 94065 (650) 649-3530

3. Related Persons

Last Name First Name Middle Name

Lanfear Dennis M.

Street Address 1 Street Address 2

Coherus BioSciences, Inc. 201 Redwood Shores Parkway, Suite

200

City State/Province/Country ZIP/PostalCode

Redwood City CALIFORNIA 94065

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Finck, M.D. Barbara K.

Street Address 1 Street Address 2

201 Redwood Shores Parkway, Suite

Coherus BioSciences, Inc.

City State/Province/Country ZIP/PostalCode

Redwood City CALIFORNIA 94065

Relationship: X Executive Officer Director Promoter

Last Name First Name Middle Name

Healy, M.D., Ph.D. James I.

Street Address 1 Street Address 2

Sofinnova Ventures 2800 Sand Hill Road, Suite 150

City State/Province/Country ZIP/PostalCode

Menlo Park CALIFORNIA 94025

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Herman Alan C.

Street Address 1 Street Address 2

Coherus BioSciences, Inc. 201 Redwood Shores Parkway, Suite

200

City State/Province/Country ZIP/PostalCode

Redwood City CALIFORNIA 94065

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Lazarus, M.D. J. Michael

Street Address 1 Street Address 2

201 Redwood Shores Parkway, Suite

c/o Coherus BioSciences, Inc.

City State/Province/Country ZIP/PostalCode

Redwood City CALIFORNIA 94065

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Montgomery George G.

Street Address 1 Street Address 2

Coherus BioSciences, Inc. 201 Redwood Shores Parkway, Suite

200

City State/Province/Country ZIP/PostalCode

Redwood City CALIFORNIA 94065

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Richards Christos

Street Address 1 Street Address 2

Levin & Company 1800 Century Park East, Suite 600

City State/Province/Country ZIP/PostalCode

Los Angeles CALIFORNIA 90067

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Satvat Ali J.

Street Address 1 Street Address 2
Kohlberg Kravis Roberts & Co. L.P. 2800 Sand Hill Road, Suite 200

City State/Province/Country ZIP/PostalCode

Menlo Park CALIFORNIA 94025

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

ZIP/PostalCode

Torres S. Edward

Street Address 1 Street Address 2

Lilly Ventures, 115 W. Washington

Street

Suite 1680 - South

City State/Province/Country

Indianapolis INDIANA 46204

Relationship: Executive Officer X Director Promoter

Relationship. Executive Officer A Director

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Troendle, M.D. August J.

Street Address 1 Street Address 2

Medpace, Inc. 5375 Medpace Way

City State/Province/Country ZIP/PostalCode

Cincinnati OHIO 45227

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Wahlstrom Mats

Street Address 1 Street Address 2

Leonard Capital, LLC 1225 Seventeenth Street, Suite 2420

City State/Province/Country ZIP/PostalCode

Denver COLORADO 80202

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing
Banking & Financial Services Biotechnology Restaurants
Commercial Banking Health Insurance Technology

Insurance Health Insurance Technology
Insurance Hospitals & Physicians Computers

Investment Banking Pharmaceuticals Telecommunications
Pooled Investment Fund X Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel an investment company under Real Estate Asial

the Investment Company

Act of 10402

Real Estate

Airlines & Airports

Commercial

Lodging & Convent

Act of 1940? Commercial Lodging & Conventions

Yes No Construction Tourism & Travel Services

Other Banking & Financial Services REITS & Finance Other Travel

Business Services Residential Other

Energy Other Real Estate Coal Mining

Energy Conservation

Electric Utilities

Environmental Services

Oil & Gas

Other Energy

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range	
No Revenues		No Aggregate Net Asset Value	
\$1 - \$1,000,000		\$1 - \$5,000,000	
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000	
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000	
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000	
Over \$100,000,000		Over \$100,000,000	
X Decline to Disclose		Decline to Disclose	
Not Applicable		Not Applicable	

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)		
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)	
Rule 505	Section 3(c)(4)	Section 3(c)(12)	
X Rule 506(b) Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)	
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)	
	Section 3(c)(7)		

7. Type of Filing

X New Notice Date of First Sale 2014-05-09 First Sale Yet to Occur Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity **Pooled Investment Fund Interests** Tenant-in-Common Securities Debt Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities X Security to be Acquired Upon Exercise of Option, Warrant or Other (describe) Other Right to Acquire Security

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient Recipient CRD Number X None

N/A None

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None

None None

> **Street Address 2 Street Address 1**

N/A N/A

State/Province/Country ZIP/Postal Code City

00000 N/A Unknown

State(s) of Solicitation (select all that apply) All States Foreign/non-US

Check "All States" or check individual States

CALIFORNIA

COLORADO

FLORIDA

MARYLAND

MASSACHUSETTS

NEW JERSEY

NEW YORK

NORTH CAROLINA

OHIO

TEXAS

13. Offering and Sales Amounts

Total Offering Amount \$65,583,048 USD or Indefinite

Total Amount Sold \$55,633,048 USD

Total Remaining to be Sold \$9,950,000 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

35

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Coherus BioSciences, Inc.	/s/ Alan C. Mendelson	Alan C. Mendelson	Secretary	2014-06-03

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.